Literature DB >> 22689835

Paraneoplastic subacute sensory neuronopathy in association with adenocarcinoma of the prostate.

Anna Cowley1, Sarah Pascoe.   

Abstract

Paraneoplastic syndromes arise infrequently in prostate cancer and paraneoplastic subacute sensory neuronopathy has not previously been reported in association with prostate cancer. When paraneoplastic syndromes occur, it is usually in the setting of small-cell carcinoma of the prostate or advanced, hormone-resistant disease. Here the authors report a 64- year-old man who developed a progressive, severe, sensory neuronopathy in the setting of a recently diagnosed stage T4 hormone-responsive prostate adenocarcinoma. Anti-Hu antibodies were positive and screening for a concurrent neoplasm at another site was negative. Sensory neuronopathy progressed, despite hormone responsiveness of his prostate adenocarcinoma, and resulted in a severe level of disability. His symptoms did not respond to intravenous corticosteroid therapy but there was a partial response to intravenous immunoglobulin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22689835      PMCID: PMC3149444          DOI: 10.1136/bcr.04.2011.4077

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

1.  Small cell prostate cancer with anti-Hu positive peripheral neuropathy.

Authors:  A D Baird; P A Cornford; T Helliwell; K A Woolfenden
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

2.  Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage.

Authors:  J H Rees
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

3.  A follow up study of patients with paraneoplastic neurological disease in the United Kingdom.

Authors:  P M Candler; P E Hart; M Barnett; R Weil; J H Rees
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

Review 4.  Paraneoplastic syndromes in prostate cancer.

Authors:  Matthew K Hong; Jennifer Kong; Benjamin Namdarian; Anthony Longano; Jeremy Grummet; Christopher M Hovens; Anthony J Costello; Niall M Corcoran
Journal:  Nat Rev Urol       Date:  2010-12       Impact factor: 14.432

5.  Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies.

Authors:  C F Lucchinetti; D W Kimmel; V A Lennon
Journal:  Neurology       Date:  1998-03       Impact factor: 9.910

6.  Neurologic complications in prostatic carcinoma.

Authors:  J R Campbell; J W Godsall; S Bloch
Journal:  Prostate       Date:  1981       Impact factor: 4.104

7.  Metastatic pure small-cell carcinoma of prostate.

Authors:  Prasanna Kumar Venkatesh; Bharat Motwani; Nada Sherman; Shan-Ching Ying; Ermias Tilahun; Jack E Garon; Lawrence Feldman
Journal:  Am J Med Sci       Date:  2004-11       Impact factor: 2.378

  7 in total
  5 in total

Review 1.  Sensory Neuronopathies.

Authors:  Allison Crowell; Kelly G Gwathmey
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-23       Impact factor: 5.081

Review 2.  Subacute sensory neuronopathy associated with Merkel cell carcinoma with unknown primary: a case report with literature review.

Authors:  Riccardo Milani; Miryam Cannizzaro; Gianluigi Arrigoni; Federica Filipello; Federica Cerri; Massimo Filippi
Journal:  J Neurol       Date:  2022-04-16       Impact factor: 6.682

3.  Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes.

Authors:  A Storstein; M Raspotnig; R Vitaliani; B Giometto; F Graus; W Grisold; J Honnorat; C A Vedeler
Journal:  J Neurol       Date:  2016-03-23       Impact factor: 4.849

4.  A Rare Case of Sensory Neuropathy Associated with Transitional Cell Carcinoma of the Bladder.

Authors:  Sujitha Ketineni; Sreenath Kodali; Sasikanth Gorantla
Journal:  Case Rep Oncol       Date:  2020-11-30

5.  Paraneoplastic sensorimotor polyneuropathy in prostatic adenocarcinoma: A case report.

Authors:  Jong Kyoung Choi; Won Jun Kim; Jae Yong Jeon
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.